TABLE 3.
Comparison of NSC-derived hMO models: Overview of selected features of hMOs approaches published in Monzel et al., 2017; Smits et al., 2019b.
| Monzel et al. (2017) | Smits et al. (2019b) | |
| Culture conditions | ||
| Used cell type | smNPCs | mfNPCs |
| Number of cells | 9,000 | 3,000 |
| Embedding | Yes | No |
| Agitation | Yes | No |
| mDANs | ||
| TH + cells* | ∼64% (d61) | ∼54% (d70) |
| Regionalization | Yes | No |
| A9/A10 specificity | Yes | Yes |
| DAT | Yes (d61) | Yes (d70) |
| D2/D3 receptor responsive | Yes | Yes |
| DA release | No | Yes |
| NM | Yes (>d149) | Yes (>d100) |
| Other cell types | ||
| Oligodendrocytes | Yes (d61) | n/a |
| Astrocytes | Yes (d61) | n/a |
| Neuronal subtypes | n/a | Yes |
Neuronal subtypes refers to the analysis whether neurons other than dopaminergic neuros are determined. As starting cell population, small molecule neural precursor cells (smNPCs) are used in Monzel et al., 2017, while Smits et al. (2019b) starts with midbrain floor plate neural progenitor cells (mfNPCs). *, different methods applied to determine and calculate TH content.